4.3 Article

[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo

Journal

ONCOTARGET
Volume 8, Issue 42, Pages 72260-72271

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.20139

Keywords

gingerol; breast cancer; cell cycle; apoptosis; animal models

Funding

  1. Sao Paulo Research Foundation (FAPESP) [2013/00798-2, 2015/24940-8]
  2. National Breast Cancer Foundation [IN-16-036]
  3. Cancer Australia [1067045]
  4. CNPq
  5. CAPES
  6. FAPESP [2012/03771-5, 2012/18908-6]
  7. National Breast Cancer Foundation [PS-17-006] Funding Source: researchfish

Ask authors/readers for more resources

There is increasing interest in the use of non-toxic natural products for the treatment of various pathologies, including cancer. In particular, biologically active constituents of the ginger oleoresin (Zingiber officinale Roscoe) have been shown to mediate anti-tumour activity and to contribute to the anti-inflammatory, antioxidant, antimicrobial, and antiemetic properties of ginger. Here we report on the inhibitory properties of [10]-gingerol against metastatic triple negative breast cancer (TNBC) in vitro and in vivo. We show that [10]-gingerol concentration-dependently induces apoptotic death in mouse and human TNBC cell lines in vitro. In addition, [10]-gingerol is well tolerated in vivo, induces a marked increase in caspase-3 activation and inhibits orthotopic tumour growth in a syngeneic mouse model of spontaneous breast cancer metastasis. Importantly, using both spontaneous and experimental metastasis assays, we show for the first time that [10]-gingerol significantly inhibits metastasis to multiple organs including lung, bone and brain. Remarkably, inhibition of brain metastasis was observed even when treatment was initiated after surgical removal of the primary tumour. Taken together, these results indicate that [10]-gingerol may be a safe and useful complementary therapy for the treatment of metastatic breast cancer and warrant further investigation of its efficacy, either alone or in combination with standard systemic therapies, in pre-clinical models of metastatic breast cancer and in patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available